✦ LIBER ✦

First-line therapy for advanced colorectal cancer

✍ Scribed by Aimery de Gramont; Christophe Tournigand; Christophe Louvet; Frédérique Maindrault-Goebel; Thierry André

Book ID: 107546404
Publisher: Current Science Inc.
Year: 2005
Tongue: English
Weight: 242 KB
Volume: 7
Category: Article
ISSN: 1523-3790
DOI: 10.1007/s11912-005-0069-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line therapy for advanced colorec

Second-line therapy for advanced colorectal cancer

✍ Geoff Chong; David Cunningham 📂 Article 📅 2005 🏛 Current Science Inc. 🌐 English ⚖ 259 KB

Radiation therapy for advanced colorecta

Radiation therapy for advanced colorectal cancer

✍ Colin A. Poulter 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Second-line therapy for advanced colorec

Second-line therapy for advanced colorectal carcinoma

✍ Naureen Starling; David Cunningham 📂 Article 📅 2005 🏛 Current Science Inc. 🌐 English ⚖ 657 KB

Third-line therapy for metastatic colore

Third-line therapy for metastatic colorectal cancer

✍ M. G. Gundgaard; J. B. Soerensen; E. Ehrnrooth 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 618 KB

Surrogate biomarkers for anti-angiogenic

Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer

✍ Christopher G. Willett; Daniel G. Duda; Rakesh K. Jain 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 130 KB

Second-line treatments after first-line

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer

✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco